SE0000782D0 - Pharmaceutical formulation and its use - Google Patents

Pharmaceutical formulation and its use

Info

Publication number
SE0000782D0
SE0000782D0 SE0000782A SE0000782A SE0000782D0 SE 0000782 D0 SE0000782 D0 SE 0000782D0 SE 0000782 A SE0000782 A SE 0000782A SE 0000782 A SE0000782 A SE 0000782A SE 0000782 D0 SE0000782 D0 SE 0000782D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical formulation
hours
active ingredient
relates
tolterodine
Prior art date
Application number
SE0000782A
Other languages
English (en)
Inventor
Lisbeth Nilvebrant
Bengt Hallen
Birgitta Olsson
Jan Stroembom
Torkel Gren
Anders Ringberg
Martin Wikberg
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/SE1999/002052 external-priority patent/WO2000027364A1/en
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE0000782A priority Critical patent/SE0000782D0/sv
Publication of SE0000782D0 publication Critical patent/SE0000782D0/sv
Priority to BR0015346-0A priority patent/BR0015346A/pt
Priority to EP00975092A priority patent/EP1227806B1/en
Priority to SI200030727T priority patent/SI1227806T1/sl
Priority to SK641-2002A priority patent/SK6412002A3/sk
Priority to AU13192/01A priority patent/AU784104B2/en
Priority to NZ518309A priority patent/NZ518309A/en
Priority to AT00975092T priority patent/ATE300941T1/de
Priority to DK00975092T priority patent/DK1227806T3/da
Priority to CA002387973A priority patent/CA2387973C/en
Priority to EEP200200245A priority patent/EE05191B1/xx
Priority to PT00975092T priority patent/PT1227806E/pt
Priority to MXPA02004574A priority patent/MXPA02004574A/es
Priority to KR1020027005973A priority patent/KR100838930B1/ko
Priority to DE60021749T priority patent/DE60021749T2/de
Priority to JP2001536139A priority patent/JP2003513918A/ja
Priority to ES00975092T priority patent/ES2245320T3/es
Priority to PCT/SE2000/002061 priority patent/WO2001034139A1/en
Priority to KR1020077019051A priority patent/KR20070091374A/ko
Priority to PL00356166A priority patent/PL356166A1/xx
Priority to CNB008154740A priority patent/CN100353935C/zh
Priority to IL14910100A priority patent/IL149101A0/xx
Priority to HU0203028A priority patent/HUP0203028A3/hu
Priority to CZ2002-1617A priority patent/CZ304671B6/cs
Priority to US09/708,428 priority patent/US6630162B1/en
Priority to NO20022264A priority patent/NO20022264D0/no
Priority to HK03106497.2A priority patent/HK1054196B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0000782A 1999-11-11 2000-03-09 Pharmaceutical formulation and its use SE0000782D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE0000782A SE0000782D0 (sv) 1999-11-11 2000-03-09 Pharmaceutical formulation and its use
HU0203028A HUP0203028A3 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use
CZ2002-1617A CZ304671B6 (cs) 1999-11-11 2000-10-24 Farmaceutický prostředek obsahující tolterodin a jeho použití
PT00975092T PT1227806E (pt) 1999-11-11 2000-10-24 Formulacao farmaceutica contendo tolterodina e sua utilizacao
DE60021749T DE60021749T2 (de) 1999-11-11 2000-10-24 Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
SI200030727T SI1227806T1 (sl) 1999-11-11 2000-10-24 Farmacevtska formulacija, ki vsebuje tolterodin in njena uporaba
SK641-2002A SK6412002A3 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use
AU13192/01A AU784104B2 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use
NZ518309A NZ518309A (en) 1999-11-11 2000-10-24 Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours
AT00975092T ATE300941T1 (de) 1999-11-11 2000-10-24 Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
DK00975092T DK1227806T3 (da) 1999-11-11 2000-10-24 Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
CA002387973A CA2387973C (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use
EEP200200245A EE05191B1 (et) 1999-11-11 2000-10-24 Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine
BR0015346-0A BR0015346A (pt) 1999-11-11 2000-10-24 Formulação farmacêutica contendo tolterodina e seu uso
MXPA02004574A MXPA02004574A (es) 1999-11-11 2000-10-24 Formulacion farmaceutica que contiene tolterodina y su uso.
KR1020027005973A KR100838930B1 (ko) 1999-11-11 2000-10-24 톨테로딘을 포함하는 약학 제제 및 이의 용도
EP00975092A EP1227806B1 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use
JP2001536139A JP2003513918A (ja) 1999-11-11 2000-10-24 トルテロジン含有医薬組成物及びその使用
ES00975092T ES2245320T3 (es) 1999-11-11 2000-10-24 Formulacion farmaceutica que contiene tolterodina y su uso.
PCT/SE2000/002061 WO2001034139A1 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use
KR1020077019051A KR20070091374A (ko) 1999-11-11 2000-10-24 톨테로딘을 포함하는 약학 제제 및 이의 용도
PL00356166A PL356166A1 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use
CNB008154740A CN100353935C (zh) 1999-11-11 2000-10-24 含托特罗定的药物制剂及其应用
IL14910100A IL149101A0 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use
US09/708,428 US6630162B1 (en) 1999-11-11 2000-11-09 Pharmaceutical formulation and its use
NO20022264A NO20022264D0 (no) 1999-11-11 2002-05-13 Farmasöytisk blanding inneholdende tolterodin, samt anvendelse derav
HK03106497.2A HK1054196B (zh) 1999-11-11 2003-09-11 含托特羅定的藥物製劑及其應用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
SE0000782A SE0000782D0 (sv) 1999-11-11 2000-03-09 Pharmaceutical formulation and its use

Publications (1)

Publication Number Publication Date
SE0000782D0 true SE0000782D0 (sv) 2000-03-09

Family

ID=26655013

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000782A SE0000782D0 (sv) 1999-11-11 2000-03-09 Pharmaceutical formulation and its use

Country Status (2)

Country Link
IL (1) IL149101A0 (sv)
SE (1) SE0000782D0 (sv)

Also Published As

Publication number Publication date
IL149101A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
HK1054196A1 (en) Pharmaceutical formulation containing tolterodine and its use
NZ504618A (en) Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
MXPA02005536A (es) Acidos aminopropilfosfinicos novedosos.
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
HU0102272D0 (en) Compositions and methods for stimulating gastrointestinal motilis
DE60220403D1 (de) Zusammensetzung zur unterdrückung von magensäure
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
SE0102440D0 (sv) New compound
WO2002102743A3 (de) Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel
HK1045464A1 (en) Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease
CA2005980A1 (en) Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
SE0000782D0 (sv) Pharmaceutical formulation and its use
BR0011845A (pt) Complexo farmacêutico
SE9202218D0 (sv) Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
IT1306186B1 (it) Sali non igroscopici di principi attivi ad attivita' terapeutica e/onutrizionale e composizioni atte alla somministrazione orale
DK0541726T3 (da) Vækstfaktorsammensætninger, fremstilling og anvendelse
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
WO2001028541A3 (en) Composition comprising sildenafil and l-arginine
RU97113692A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств